NSCLC
We selected NSCLC cell lines--A549 (KRAS G12S), NCI-H3255 (EGFR L858R), NCI-H3122 (EML4-ALK E13;A20), and HCC78 (SLC34A2-ROS1)-to evaluate the antiproliferative effects of submicromolar concentrations of the multitargeted TKIs imatinib, sorafenib, erlotinib, and crizotinib.
We selected <span class="disease" id="22617245-3-12-17">NSCLC</span> cell lines--A549 (KRAS G12S), NCI-H3255 (EGFR L858R), NCI-H3122 (<span class="gene" id="22617245-3-83-87">EML4</span>-ALK E13;A20), and HCC78 (SLC34A2-ROS1)-to evaluate the antiproliferative effects of submicromolar concentrations of the multitargeted TKIs imatinib, sorafenib, erlotinib, and crizotinib.